Approaches in Gene Therapy of Cancer and Cardiovascular Diseases by Gardlik , Roman et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
5 
Approaches in Gene Therapy of Cancer and 
Cardiovascular Diseases 
Gardlik Roman1, Dovinova Ima2 and Chan Julie Y.H. 3 
1Institute of Molecular Biomedicine, Faculty of Medicine  
Comenius University, Bratislava,  
2Institute of Normal and Pathological Physiology, Slovak Academy  
of Sciences, Bratislava, 
3Center for Translational Research in Biomedical Science, Chang-Gung  
Memorial Hospital, Kaohsiung Medical Center, Kaohsiung,  
1,2Slovakia 
3Taiwan 
1. Introduction 
In this chapter we will focus on few topics. First, we summarize and discuss angiogenic 
gene therapy of cancer and cardiovascular diseases, with RNA interference in a separate 
section. Second, we briefly review delivering systems in gene therapy, their advatages and 
limitations and further focus on bacterial vectors. Last, we summarize antioxidant gene 
therapy of cardiovascular diseases and hypertension. 
Considering the fact that the fundamental discoveries and new findings in medicine are 
being crystallized on genetic and genomic levels, gene therapy is one of the potential 
mechanisms for therapeutic intervention. Gene therapy in a broad sense, i.e. all the 
therapeutic strategies employing nucleic acids as carriers of genetic information, found its 
utilization in most areas of medicine, including angiogenesis research. Similarly to classical 
“non-gene“ therapy, the research in gene therapy is happening on the preclinical level using 
appropriate animal models, with cancer and cardiovascular diseases being the most 
abundant indications. There are several different strategies known. Besides the delivery of 
therapeutic gene (replacement of the mutated gene by a functional one or delivery of the 
gene because of lack of the gene product), novel strategies are also being widely used based 
on blocking the function of a specific gene by application of RNA interference inducing 
sequences, antisense inhibition etc.  
One of the key advantages of gene approaches is the endogenous production of the 
therapeutic molecule. Furthermore, targeted gene delivery specifically into the target tissue 
or only to a certain cell type can dramatically decrease the likelihood of adverse effects. 
Along with the development of new vectors and regulatory systems, the ability to control 
the expression of therapeutic gene in time and space is being improved. This is of great 
importance in affecting such complex and complicated processes as angiogenesis. Currently, 
almost three quarters of indications addressed by gene therapy clinical trials are represented 
by cancer and cardiovascular diseases 
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2. Angiogenic gene therapy 
After birth, angiogenesis still contributes to organ growth. However, in adults, the majority 
of blood vessels remains in quiescence with the most active angiogenesis during 
menstruation cycle in the uterus and pregnancy in the placenta. In spite of this, endothelial 
cells do preserve the ability to quickly proliferate and react to physiological stimulus such as 
hypoxia and inflammation. 
If the stimulus is too excessive, the fine balance between stimulants and inhibitors can be 
disrupted and thus lead to so-called “angiogenic switch”. The best described pathological 
states with dysregulated angiogenesis include cancer, cardiovascular disorders, 
inflammatory eye disorders as well as many other processes such as obesity, metabolic 
diseases, asthma, diabetes mellitus, cirrhosis, sclerosis multiplex, rheumatoid arthritis, 
macular degeneration, psoriasis, atherosclerosis, restenosis, diabetic retinopathy, 
endometriosis, bacterial infections and autoimmune diseases (Cao, 2010; Webb & Vande 
Woude, 2000). 
2.1 Gene therapy of cancer 
Gene therapy-based angiogenesis inhibiting strategies have gained much attention thanks to 
their advantages over the conventional antiangiogenic treatments. Given that effective 
inhibition of pathological angiogenesis requires long term treatment, gene therapy may be 
of importance for selective gene transfer to the affected areas and prolonged expression of 
therapeutic genes. Apart from that, gene therapy provides a possibility to circumvent the 
issues associated with recombinant proteins production, stability and solubility. Gene 
transfer allows for appropriate folding and stability of encoded proteins in vivo in the 
natural environment. An interesting advantage is also the ability to selectively target the 
gene transfer into certain tissues enabling localized expression and high regional drug 
concentration without increasing systemic levels. One of the key justifications for using gene 
therapy is also an insufficient efficiency of “non-gene“ therapies based on inhibition of 
VEGF and other growth factors signal pathways in humans (Gridelli et al., 2007). The most 
commonly used gene therapy approach in cancer is so called suicide cytotoxic therapy using 
thimidin kinase or other chemosensitizing genes that allow the conversion of inactive 
prodrug (ganciclovir) into a cytotoxic product (Both, 2009). 
2.1.1 Preclinical studies 
Antiangiogenic gene therapy of cancer has been tested on a preclinical level in various 
carcinogenesis models. Most of the studies performed so far have used viral vectors 
(adenoviruses, retroviruses, lentiviruses, adeno-associated viruses, herpes simplex viruses) 
encoding endogenous angiogenesis inhibitor genes such as cytokines/chemokines (IFN-┙, 
IFN-┚, IFN-┛, CXCL10, IL-12, IL-18, TNF-┙), VEGF blockers (sFlt-1, Flk-1), proteolytic 
fragments (angiostatin, endostatin, vasostatin, tumstatin) and others (Persano et al., 2007). 
For example, in a colorectal cancer model an adenovirus-based therapy using genes 
encoding IFN-┚ (Tada et al., 2001) and endostatin (Oliner et al., 2004) as well as plasmids 
encoding Flk-1 (W.J. Kim et al., 2006) and tumstatin (Yao et al., 2005) have been successfully 
applied. In a model of malignant melanoma, retrovirus vectors carrying gene encoding 
CXCL10 (Feldman et al., 2002) and plasmids encoding vasostatin (Jazowiecka-Rakus et al., 
2006) and MCP-1 (Koga et al., 2008) genes have been successfully used, all exerting a clear 
antiangiogenic effect. Recently, a systemically available antiangiogenic gene therapy using 
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adenovirus bearing soluble VEGF receptor gene has been proven to be effective in 
suppressing tumor growth in various oral cancer cell line xenografts in mice (Okada et al., 
2010). 
Several studies have been performed using gene delivery of endogenous angiogenesis 
inhibitor endostatin. A liposome-encapsulated adenovirus encoding endostatin was applied 
in therapy of ovarian cancer (Yang et al., 2010). Systemic administration was well-tolerated 
and resulted in marked suppression of tumor growth, which was associated with a 
decreased number of micro-vessels and increased apoptosis of tumor cells. An interesting 
novel therapeutic approach for pancreatic cancer has been employed in a study using 
vaccinia virus encoding the endostatin-angiostatin fusion gene (Tysome et al., 2009). Besides 
high selectivity of the used vector, inhibition of angiogenesis and a clear antitumor potency 
has been observed. In another study, combined antiangiogenic and proapoptotic gene 
therapy involving endostatin and sTRIAL (soluble tumor necrosis factor-related apoptosis-
inducing ligand) effectively suppressed hepatocellular carcinoma growth and angiogenesis 
in nude mice (Zhang et al., 2009). At last, adenovirus-mediated endostatin gene delivery 
combined with cisplatin treatment was effective in a lung cancer murine model (Ning et al., 
2008). These studies represent a future direction in cancer research in which instead of 
targeting a single molecule, a combinatorial approach targeting multiple factors and/or an 
additional therapeutic approach is applied to cover multiple pathways of cancer 
progression. 
2.1.2 Clinical studies 
Despite a relatively high number of clinical studies using cancer gene therapy, specifically 
antiangiogenic gene therapy has only been exploited in a few studies. Intratumoral injection 
of adenovirus encoding immunostimulatory cytokine IL-12 has been tested in patients with 
advanced gastrointestinal cancer (liver, colorectal, pancreatic tumors) in phase I study 
(Sangro et al., 2004). Therapy was well tolerated, although only a moderate antitumor effect 
was observed. In another study, plasmid bearing IL-12 gene was applied to patients with 
malignant melanoma (Heinzerling et al., 2005). In two out of nine patients, the disease was 
stabilized for period of over three years and a complete remission was achieved in one 
patient. In these patients, a localized reduction in angiogenesis has been proven by 
immunohistochemistry. However, the rest of the patients showed only temporal response to 
the therapy. A recent phase I clinical trial of IL-12 plasmid/lipopolymer complexes has also 
shown a clinical benefit in treatment of recurrent ovarian cancer without adverse events 
(Anwer et al., 2010). In a different phase I study, adenovirus vector carrying IFN-┚ gene has 
been used in therapy of malignant pleural mesothelioma (Sterman et al., 2007). In all the 
above-mentioned studies, however, inhibition of angiogenesis was not the primary goal, yet 
a part of the antitumor effect. 
2.2 Gene therapy of cardiovascular diseases 
In view of the many advances in explaining the molecular mechanisms of angiogenesis high 
hopes were put in gene therapy. However, in the clinical studies with genes encoding for 
individual proangiogenic growth factors (similar to recombinant proteins) only moderate 
success has been observed so far, thus creating a space for development of new vectors and 
alternative approaches (Vincent et al., 2007).  
Progress in the field of gene therapy for cardiovascular disease has been modest; one of the 
key reasons for this limited progress is the lack of gene delivery systems for localizing gene 
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therapy to specific sites to optimize transgene expression and efficacy. However, progress 
toward the site-specific delivery of cardiovascular gene therapy is still ongoing and 
promising novel approaches are being tested (Fishbein et al., 2010). 
2.2.1 Preclinical studies 
A lot of studies have been performed on a preclinical level with very promising results. 
Angiogenic gene therapy using intramuscular injection of plasmids encoding VEGF and 
plasminogen activator has been applied in a mouse model of myocardial infarction (ligation 
of coronary artery) and hind limb ischemia (ligation of arteria femoralis) (Traktuev et al., 
2007). Authors were able to detect functionally significant angiogenesis that clearly 
improved the pathological consequences of disease induction. The model of hind limb 
ischemia is actually a commonly used model to prove the efficiency of proangiogenic viral 
and non-viral gene delivery in ischemic disease (Schgoer et al., 2009). Bosch-Marce et al., 
have used this model to test adenovirus vector carrying the gene encoding for constitutively 
active HIF-1┙, resulting in a sufficient induction of reperfusion of the affected areas even in 
older animals (Bosch-Marce et al., 2007). These results suggest that the HIF-1┙ activity is 
necessary and sufficient for mobilization of angiogenic cells and that gene therapy using 
HIF-1┙ gene can compensate the pathological effects of ageing. Gene therapy using gene 
encoding VEGF has further shown a clear beneficial effect in a rat model of myocardial 
infarction (Tang et al., 2010). In a mouse model of myocardial infarction, the ultrasound-
targeted gene delivery of VEGF or stem cell factor resulted in increased vascular density and 
improved myocardial perfusion and ventricular function (Fujii et al., 2009). Yockman et al., 
used an ischemia-inducible plasmid construct expressing VEGF to treat myocardial 
ischemia and infarction (Yockman et al., 2009). Ischemia-inducible system was superior to 
constitutively expressed gene construct in reducing the infarct size. A different regulation 
system for VEGF gene delivery based on tetracycline-inducible AAV-based vector has been 
employed by Tafuro et al., in a hind limb ischemia model (Tafuro et al., 2009). These results 
clearly indicate that the fine tuning of VEGF expression is required to achieve the formation 
of a stable vasculature able to sustain functional neovascularization. Hypothesizing that the 
transient nature of VEGF gene expression provokes instability of neovasculature, Olea et al., 
compared single vs. repeated transfection in a rabbit model of hind limb ischemia by 
injecting a plasmid encoding human VEGF165 (Olea et al., 2009). Repeated, but not single, 
VEGF gene transfection resulted in increased microvasculature, which in turn afforded 
effective protection against ischemic muscle damage. Pajusola et al., have compared the 
virus vector-mediated delivery of genes encoding VEGF and HIF-1┙ into the muscle of mice 
(Pajusola et al., 2005). Results of this study show that HIF-1┙ gene therapy is able to ensure 
increased expression of numerous proangiogenic molecules and, thus, can circumvent the 
shortcomings associated with overexpression of a single growth factor. A rationale for 
combination proangiogenic therapy has been provided in two studies, in which a synergistic 
effect of concurrent application of plasmids encoding FGF-2 and PDGF-BB by intramuscular 
injection was observed in a rabbit/rodent hind limb ischemia model (Li et al., 2010). 
2.2.2 Clinical studies 
Results from several interesting clinical studies have been published recently. In a phase I 
study testing the safety of intramuscular injection of VEGF-encoding plasmid vector in 9 
patients suffering from serious peripheral arterial disease of the lower extremities a 
significant improvement in most of the measured parameters has been observed regardless 
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of the dose (Kim et al., 2004). However, the serum VEGF levels were not elevated and the 
control group was missing in that study. Interestingly, no significant improvement in 
primary and secondary endpoints between groups was achieved in two recent multicenter, 
double-blind, placebo-controlled phase II trials exploring intramuscular application of 
plasmid encoding angiogenic factors (Grossman et al., 2007; Rajagopalan et al., 2003). 
Authors of Euroinject One phase II trial analyzed the effect of gene transfer using plasmid 
encoding VEGF165 gene on myocardial perfusion, left ventricle function and clinical 
symptoms in 80 patients suffering from stable severe ischemic heart disease (Kastrup et al., 
2005). A direct intramyocardial injection of plasmid did not improve the study endpoints 
compared to placebo, although a regional improvement in ventricle wall movement was 
achieved. Results thus show the safety of direct intramyocardial injection, but not the 
efficiency. In the REVASC trial, a total of 67 patients with ischemic heart disease and severe 
angina pectoris were enrolled to the study (Stewart et al., 2006). Here, the intramyocardial 
injection of replication-deficient adenovirus vector bearing VEGF121 gene significantly 
ameliorated the primary endpoint (exercise time needed for 1mm ST segment depression) as 
well as overall exercise time and exercise time to moderate angina after 26 weeks of therapy 
in patients with exercise-induced ischemia. On the other hand, in a recent double-blind, 
placebo-controlled study VEGF gene therapy failed to improve perfusion of ischemic 
myocardium in patients with advanced coronary artery disease (Stewart et al., 2009). 
Further, intramuscular injection of plasmid with VEGF gene was compared against placebo 
(saline) in 54 diabetic patients suffering from severe peripheral arterial disease (Kusumanto 
et al., 2006). Although a significant improvement of some of the parameters (hemodynamic 
status, skin ulcerations) has been achieved, the primary endpoint of this study – amputation 
of lower extremity after 100 days – stayed unchanged. Moreover, long-term safety of VEGF 
gene therapy has been proven in an eight-year safety follow-up of coronary artery disease 
patients after intracoronary VEGF gene transfer (Hedman et al., 2009). Local intracoronary 
VEGF gene delivery is, thus, considered safe and does not increase the risk of major adverse 
cardiovascular events, arrhythmias, cancer, diabetes or other disease. 
So far the only clinical study testing the delivery of HIF-1┙ gene was a randomized, double-
blind, placebo-controlled phase I trial enrolling 34 patients with peripheral arterial disease 
(Rajagopalan et al., 2007). Treatment based on direct intramuscular administration of 
adenovirus vector carrying the HIF-1┙ gene was well tolerated and provided relief of rest 
pain one year after the therapy, supporting the necessity for more clinical trials. 
The second generation of angiogenic gene therapeutics is represented by constructs enabling 
the expression of two or more proangiogenic cytokines. Analogous to gene therapy using 
the master regulatory gene HIF-1┙, these “multivalent” approaches may provide a benefit 
against the classical “monovalent” ones (Vincent et al., 2007).  
Overall, we might conclude that only slight clinical benefit of gene therapy in cardiovascular 
diseases has been observed so far on the level of multicenter, randomized, placebo-
controlled clinical trials. This finding, however, is in direct contrast to promising and 
convincing results from preclinical studies and, thus, further stimulates searching for new 
and alternative approaches in experimental as well as clinical settings. New viruses have 
been introduced and new results have been collected from preclinical and clinical studies. 
Recent results from preclinical developments and clinical trials have been reviewed 
(Karvinen & Yla-Herttuala, 2010). 
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2.3 RNA interference in therapeutic modulation of angiogenesis 
Since the first discoveries of RNA interference mechanism (RNAi) 13 years ago, much new 
information has shown up and a new age of gene therapy, in broad sense, has actually 
begun. This molecular phenomenon found its usage, besides in functional genetic studies, 
also in therapy based on silencing the expression of disease-causing genes (so called gene 
knock-down).  
One of the main obstacles in achieving in vivo gene silencing using RNAi is the means of 
delivery. The siRNA molecules are, if present outside the cell, unstable and are subject to 
rapid degradation. Therefore, they are being chemically modified or incorporated into 
vectors like in the case of classical gene delivery. Within such a vector siRNA are encoded as 
so called short hairpin RNA (shRNA) that are expressed inside the target cell. 
One of the break-through experiments was based on intravenous administration of 
chemically modified siRNA against endogenous apolipoprotein B (apoB) in mice leading to 
apoB mRNA silencing in liver and jejunum as well as decrease in plasma levels of apoB and 
overall cholesterol (Soutschek et al., 2004). These siRNA even reduced the expression of 
human apoB in transgenic mice, and the results further extended the potential of RNAi-
based therapy of not only cardiovascular diseases.  
Several studies have been performed to test the efficiency of RNAi in therapy/prevention of 
cardiovascular diseases. It is known that activation of NFkappaB pathway can be associated 
with development of cardiac hypertrophy and its transition to heart failure. Intramyocardial 
delivery of shRNA against NFkappaB in lentiviral vector has led to regression of cardiac 
hypertrophy in transgenic mice, suggesting the potential role of NFkappaB as a therapeutic 
target in prevention of hypertrophy/heart failure (Gupta et al., 2008). Similar results have 
been observed in a model of pressure-induced hypertrophy using systemic administration 
of siRNA against focal adhesion kinase (FAK), which acts as one of the hypertrophy 
mediators (Clemente et al., 2007). In the work of Jiang et al., it was even proven that RNAi 
against HIF-1┙ inhibits the formation of foam cells in vitro, indicating that induction of HIF-
1┙ by atherogenic factors may be a key step in coordinating the cellular processes leading to 
atherosclerotic lesions (Jiang et al., 2007). An alternative approach was tested in a study of 
Natarajan et al., that, instead of using constitutively active HIF-1┙, reduced the activity of 
HIF-1┙ prolyl hydroxylases by RNA interference (Natarajan et al., 2006). Small interfering 
RNAs (siRNA) managed not only to activate HIF-1┙ signaling in vitro, but also rescued the 
endangered myocardium in a mouse model of overall ischemia. Thus, the authors proved 
that indirect activation of HIF-1┙ signaling is not only possible, but also efficient. In another 
study the systemic administration of siRNA against ┚1-adrenergic receptors has been 
proven to be specific for ┚1 receptors expression without influencing ┚2 receptors (Arnold et 
al., 2007). This therapy significantly reduced the hypertrophy and the blood pressure in 
spontaneously hypertensive rats. Moreover, preventive application of ┚1-specific siRNA 3 
days before myocardial infarction improved the heart function and reduced cardiomyocyte 
apoptosis.  
Antiangiogenic therapy using RNAi has found its broad experimental application (Hadj-
Slimane et al., 2007). Silencing of HIF-1┙ by RNAi leads to transient stasis or regression of 
tumors in vivo and silencing in early stage tumors is more effective than in stable tumors (Li 
et al., 2005). In addition, siRNA against HIF-1┙ inhibit the expression of this transcription 
factor in cancer cells and in endothelial progenitor cells even in hypoxic conditions, when it 
is naturally activated. At the same time, differentiation, proliferation and migration of these 
cells are also inhibited. Effectiveness of anticancer therapy using siRNA against VEGF 
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(naked or within a vector) has been proven to be effective in vitro and in vivo in a number of 
cancer models. Furthermore, a combination of oncolytic virus therapy and VEGF specific-
siRNA has also been proven to be effective in vitro and in vivo (Yoo et al., 2007). Based on 
different physiological roles of VEGF family members, a combination therapy with siRNA 
vectors against VEGF-A and VEGF-C was used to suppress lymph node and metastasis in a 
mouse metastatic breast cancer model (Shibata et al., 2008). Another combined approach has 
been successfully used by Chen et al., in therapy of laryngeal squamous cell carcinoma by 
concurrent application of plasmids encoding siRNA against VEGF, hTERT and Bcl-xl (Chen 
et al., 2008). 
One of the most important papers in recent years was the study of Kleinman et al., who have 
reported a sequence- and target-independent angiogenesis suppression by siRNA via toll-
like receptor 3 (TLR3) (Kleinman et al., 2008). Here, the non-targeted siRNA suppressed 
dermal neovascularization in mice as effectively as VEGF siRNA. The effect was mediated 
through cell surface TLR3, its adaptor TRIF and induction of IFNgamma and IL-12. These 
results suggest that all siRNA-based RNAi strategies activating TLR3 have to face non-
specificity, which, however, does not have to be considered a disadvantage. Even though a 
specific silencing is desired, a different approach/vector should be used to avoid activating 
of TLR3 pathway. Bacterial vectors are characterized by cellular entry into the host cell, 
where they can mediate their therapeutic effects. Thus, bacteria can represent an ideal 
system for delivery of RNAi. 
Apart from RNAi, another big area of small RNA-related research that is gaining much 
more attention these days is the microRNA research. More importantly, microRNA have 
been found to play a key role in regulation of angiogenesis, both in cancer and ischemic 
diseases, indicating that the development of clinically relevant therapies can be expected in 
a short time period (Fasanaro et al., 2010).  
3. Delivery systems 
Vectors for transfer of therapeutic sequences into target cells can be divided into three basic 
groups: viral, non-viral (naked DNA) and bacterial. Each of these groups has different 
research and therapeutic indications, and features specific pros and cons (Gardlik et al., 2005 
Chailertvanitkul and Pouton, 2010). Currently, the most frequently used vectors in gene 
therapy clinical trials include: adenoviruses (400 clinical trials; 23,8%), retroviruses (344 
clinical trials; 20,5%), naked/plasmid DNA (304 clinical trials; 17,7%), adeno-associated 
viruses (75 clinical trials; 4,5%) and others (John Wiley & Sons, 2010). 
Adenoviruses are the most commonly used gene-delivery vectors due to the efficiency of 
their in vivo gene transfer their ability to deliver double-stranded DNA to the nucleus 
efficiently. In addition, their large genome allows for extensive modification and 
incorporation of therapeutic genes. Since 1993, about 300 protocols using an adenoviral 
vector have been performed, although they have yet to be proven effective in clinical trials. 
By 2009 over 350 protocols had been approved for clinical trials of gene therapy using 
attenuated adenoviral vectors, 210 of which were open, but only 5 of which were  
Phase III trials (for details see the Clinical Trials Worldwide Database at 
http://www.wiley.co.uk/genmed/clinical). 
The adenovirus-based vector has been continuously improved by modification of the 
adenoviral genome and capsid, and novel adenovirus-delivery systems have been recently 
proposed (Shirakawa, 2008). Since their first clinical trial 20 years ago, retroviral vectors 
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have now been used in more than 350 gene-therapy studies. Retroviral vectors are 
particularly suited for gene-correction of cells due to long-term and stable expression of the 
transferred transgene(s), and also because little effort is required for their cloning and 
production. Despite several unsuccessful attempts using retroviral therapeutics, a new 
generation of vectors with improved genome integration and safety characteristics are now 
available, making them a useful tool for several gene therapy applications (Maier et al., 
2010). On contrary, adeno-associated vectors (AAV) are characterized by low frequency of 
random integration into the genome and moderate immune response. This makes AAV an 
attractive platform for vector design. Like in most other vector systems, the tropism of AAV 
vectors limits their utility for certain tissues especially upon systemic application. However, 
the tropism can be modified by targeted capsid modification and the use of different 
serotypes, thus making them a good cell-type specific delivery system (Michelfelder & 
Trepel, 2009).  
Another group of delivery systems includes bacterial vectors (Gardlik et al., 2005). Owing to 
the specific ability of some bacterial strains to colonize hypoxic areas, bacteria found their 
primary application mainly in cancer therapy (Gardlik & Fruehauf, 2010). A number of 
experimental studies have been published to date and several clinical studies employing 
bacterial therapies are currently ongoing. Apart from live bacterial delivery systems, empty 
envelopes of Gram negative bacteria, so called bacterial ghosts are also being explored as a 
potential tool for gene delivery (Kudela et al., 2010). In the upcoming sections we 
specifically focus on modulation of angiogenesis-related events using bacterial vectors. 
3.1 Bacteria – mediated gene therapy 
The first attempts at using bacteria for therapeutic purposes were made more than 40 years 
ago. At this time, it was discovered that bacteria could predominantly replicate in solid 
tumors (Moese & Moese, 1964). However, the first indications of this phenomenon date back 
to 19th century. These findings remained largely unexplored until the turn of 20th century, 
when oncolytic bacteria capable of lysing host cells were first studied by various research 
groups (Theys et al., 2001; Yazawa et al., 2000).  
Despite recent progress, only a few recent studies on bacterial tumor therapy have focused 
on antiangiogenic therapy. Although effects on the vasculature were observed in most of 
these studies, these changes seemed to be a consequence mainly of bacteria-mediated 
therapy. Bacteria-mediated antiangiogenesis tumor therapy, however, is a reasonable 
approach given that solid tumors are often characterized by increased vascularization. 
Herein we summarize latest research on cancer therapy using genetically modified bacteria 
with particular emphasis on the potential of blocking tumor angiogenesis. 
3.2 Bacteria affecting angiogenesis 
Pronounced angiogenesis is one of the hallmarks of solid tumors. Therefore, in order to 
search for more efficient anticancer drugs efforts are being made to block tumor 
angiogenesis. Despite notable successes achieved in studies using oncolytic bacteria for 
cancer treatment, bacteriolytic therapy in and of itself is often insufficient for complete 
eradication of experimental tumors (Agrawal et al., 2004). The idea of using combined 
therapy with bacteria and angiogenesis inhibition has therefore been suggested. 
Below are reviewed four different approaches for using modified bacteria as anticancer 
therapeutics – bactofection, DNA vaccination, alternative gene therapy and bactoference – 
with a focus on angiogenesis suppression (Figure 1). 
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Fig. 1. Antitumor effect of bacteria colonizing tumor tissue. Auxotrophic bacteria specifically 
colonize tumors with necrotic and hypoxic areas (panel on the left). The anticancer effect of 
bacteria can be exerted in four different ways: (a) Bactofection – after escaping the vessel 
and entering the target cell, bacteria disrupt and release a plasmid vector encoding the 
therapeutic gene. The plasmid is transferred into the cell nucleus and the therapeutic protein 
is expressed by the host cell’s expression system (blue square symbol). (b) DNA vaccination 
– bacteria deliver therapeutic plasmid into the host cell in a similar way as in bactofection. 
The host cell may in this case be an antigen presenting cell. The plasmid encodes a tumor 
cell-expressed antigen to help prime a T-cell response against the tumor antigen which is 
present on the surface of tumor cells leading to induction of humoral and cellular immune 
response against the tumor. (c) Bacterial protein delivery – bacteria, either in extracellular 
environment or inside tumor cells, express the therapeutic gene directly and serve as protein 
delivery vehicles (red square symbol). (d) Bacterial delivery of RNA interference – bacteria 
deliver plasmid encoding shRNAs or express the shRNAs to induce RNA interference 
against an oncogene or a tumor-expressed factor. 
3.3 Bactofection 
The use of bacteria as a vector for the delivery of therapeutic genes to target cells is known 
as bactofection, and several studies have used this approach to deliver genes encoding 
antiangiogenic molecules to tumor cells in vivo. A study was made using Salmonella choleraesuis 
strain bearing gene encoding endostatin on eukaryotic expression plasmid (Lee et al., 2004). 
The expression of endostatin was targeted exclusively to tumor tissues colonized by bacteria 
and significant inhibition of tumor growth (40-70%) with decreased intratumoral microvessel 
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density and reduced expression of vascular endothelial growth factor (VEGF) was observed. 
Bactofection using auxotrophic salmonellae as vectors has also been effectively employed for 
therapy of experimental tumor models using expression plasmids carrying various cytokine 
genes such as IL-12 and GM-CSF (Yuhua et al., 2001), IL-4 and IL-18 (Agorio et al., 2007) or 
other molecules playing role in angiogenesis, such as Flt3 ligand (Yoon et al., 2007). Further, a 
dual tumoricidal and antiangiogenic effect of S. choleraesuis carrying an expression plasmid 
containing the thrombospondin-1 gene under control of eukaryotic promoter was observed in 
a murine model of malignant melanoma (Lee et al., 2005). A potential limitation of bactofection 
for cancer therapy is the fact that the effector molecule will likely be expressed exclusively in 
cells infected by bacteria, leaving a potentially large population of tumor cells untreated. 
However, if the product of the transgene is secreted outside the target cell, it may still have a 
therapeutic effect on non-infected tumor cells.  
3.4 DNA vaccination 
It is known that bactofection of plasmids encoding a tumor-expressed antigens can lead to 
induction of humoral and cellular immune response in the host thereby providing 
protective defense against tumors (R. Xiang et al., 2000). This approach, termed DNA 
vaccination, has been successfully implemented for antiangiogenic therapy. Oral 
antiangiogenic bacterial vaccines directed against VEGFR-2 were proven to be efficacious in 
animal models of malignant melanoma, colorectal carcinoma and lung cancer (Niethammer 
et al., 2002) as well as non-cancer diseases like stromal keratitis (Kim et al., 2006) and 
atherosclerosis (Petrovan et al., 2007). Furthermore, salmonella-mediated vaccination 
against murine VEGFR-2 has been successfully combined with classical gene therapy for the 
treatment of malignant melanoma (Lu et al., 2008). Bacterial vaccines directed against the 
apoptosis inhibitor survivin (Xiang et al., 2005) and the TGF-┚1 co-receptor endoglin (Lee et 
al., 2006) also proved to be effective in inhibition of tumor angiogenesis. Taken together, 
these findings underscore the key role of angiogenesis in cancer as well as other diseases 
and, at the same time, highlight the complexity of this essential process.  
3.5 Alternative gene therapy 
Another means of using bacteria for gene therapy is the so-called alternative gene therapy 
(AGT) approach, which is also known as bacterial protein delivery (Palffy et al., 2006). It is 
based on transfer of bacterially expressed therapeutic proteins to the host organism using 
genetically modified (transformed) bacteria. As with bactofection, AGT is mostly used for 
treatment of tumors and employs primarily oncolytic and tumor-colonizing bacterial strains of 
Clostridia, Bifidobacteria or Salmonellae (Theys et al., 2001; Zheng et al., 2000). Li et al., 
successfully used Bifidobacterium adolescentis as a vector for the expression of endostatin within 
tumors (Li et al., 2003). These authors showed a strong inhibition of angiogenesis was able to 
significantly to inhibit local tumor growth. In another study, Bifidobacterium longum was shown 
to efficiently deliver the antiangiogenic protein endostatin to murine liver tumors, and induce 
antitumor activity (Fu et al., 2005). Furthermore, the antitumor effect was enhanced by co-
administration of the same bacterial strain expressing tumor necrosis factor-related apoptosis 
inducing ligand (TRAIL) (Hu et al., 2009). These findings emphasize the need for combination 
therapy, in which multiple antitumor pathways are inhibited. In situ production of cytokines 
by bacteria represents a cost-effective and safe alternative mainly to systemic administration 
which can be associated with unwanted side-effects. However, in recent study employing 
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Listeria monocytogenes as a vehicle for tumor specific gene and protein delivery, bactofection 
proved to be more efficient than AGT (Stritzker et al., 2008).  
Interestingly, previously unknown antiangiogenic effects have recently been discovered for 
a variety of molecules involved in the immune response and cellular apoptosis mainly due 
to extensive ongoing research in the field of cancer therapy. Bacteria in gene therapy, 
differences between bactofection and AGT, advantages and disadvantages as well as 
specific application of both approaches are discussed in detail in our review article (Palffy et 
al., 2006).  
In spite of great success in a preclinical setting, the application of bacteria for human tumor 
therapy has not been particularly efficacious, although this approach was well tolerated in 
most studies (Cunningham & Nemunaitis, 2001; Nemunaitis et al., 2003; Toso et al., 2002). In 
light of above-mentioned findings, however, we would suggest that angiogenesis would be 
a meaningful target for further experimental and clinical studies of bacteria-mediated 
anticancer therapy, particularly if used in conjunction with oncolytic strains of bacteria. 
3.6 Bactoference – bacteria-mediated RNA interference 
A promising new approach for bacteria-mediated anticancer therapy is the combination of 
two distinct methodologies: bacteriotherapy and RNA interference. Bacteria that have 
engineered to produce and deliver short interfering RNA (siRNA) represent a novel tool for 
the efficient induction of RNA interference (RNAi) in host cells. This concept herein termed 
“bactoference” was first tested at the in vitro level in 2005 by Zhao et al., (Zhao et al., 2005). 
These authors showed that siRNAs produced by invasive E. coli strain could induce RNAi 
against in mammalian cell cultures. The first in vivo demonstration of bactoference was 
provided by Xiang et al., who showed that invasive E. coli capable of producing beta-catenin 
shRNA could induce RNAi in colonic epithelial cells and colonic tumors xenografted into 
nude mice (Xiang et al., 2006). To date, however, bactoference has not been used to directly 
target angiogenesis, although some of the targets explored (beta-catenin, STAT3 and bcl-2) 
are known to augment angiogenesis via their effects on the expression of various 
proangiogenic factors. Thus, antitumor effects of knocking down these targets may, in part, 
be related to suppression of blood vessel formation. However, a number of studies using 
“non-bacterial” application of siRNA against VEGF (Jia et al., 2007), HIF-1┙ (Jiang et al., 
2006) and other angiogenesis-related molecules indicates that inhibition of endothelial cell 
proliferation and new blood vessel formation is a viable target for RNAi-based treatment of 
cancer as well as other diseases.  
4. Antioxidant gene therapy 
Reactive oxygen and nitrogen species may remodel the extracellular matrix and blood 
vessels, cause endothelial dysfunction, induce apoptosis, exacerbate inflammatory reaction, 
regulate cell proliferation and key signal transduction pathways, and inhibit histone 
deacetylase activity involved in hypertension (Cohen and Tong, 2010; Fostermann, 2010).  
Overproduction of reactive oxygen species plays an important role in a number of 
cardiovascular pathologies, including hypertension, atherosclerosis, myocardial infarction, 
ischemia/reperfusion injury, and restenosis after angioplasty.  
In this section we focus on gene therapy research using experimental models of 
cardiovascular diseases and hypertension.  
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4.1 NO levels and the superoxide dismutases 
There are at least two major strategies of modulation of nitric oxide (NO) levels in 
hypertension and cardiovascular diseases: (i) modulation of NO levels by NO synthase 
(NOS) stimulation, increase in NO bioavailability, administration of NO donors or 
precursors, and NOS gene incorporation; (ii) scavenging of superoxide and suppression of 
oxidative stress by activation of antioxidant gene expression or by suppression of selected 
genes via knock-out or RNA silencing (Dovinova, Gardlik et al., 2009).  
NO reacts with superoxide at a rate three times faster than the dismutation of superoxide by 
superoxide dismutase (SOD). Because of the efficiency of the reaction, the local 
concentration of SOD is a key determinant of bioactivity (the biological half-life) of NO. 
Individual SOD isoform in different cell compartments (cytosol, mitochondria, extracellular 
space) protects against superoxide-mediated cytotoxicity and functioning as a signaling 
molecule (Mendez, 2005). SOD enzymes therefore play an important role in cardiovascular 
tissue by protecting NO against oxidative inactivation by superoxide and they are important 
in vasodilatation and in the protection of NO bioactivity in blood vessel walls (Gongora & 
Harrison, 2008).  
Gene transduction of individual SOD genes (Chu et al., 2003; Zimmerman et al., 2004; 
Dovinova et al., 2008; Kamezaki et al., 2008) or combination of both SOD and NOS 
transgenes (Kung et al., 2008,) has positive influence on experimental hypertension. This 
protective effect is the end results of an increase in tissue level of NO and the decreases in 
oxidative stress (Chan et al., 2006) and peroxynitrite production (a cytotoxic molecule 
generated by reaction between superoxide and NO) (Kishi et al., 2004). The SOD genes are 
the first natural antioxidant defenses of an aerobic cellular system. The following subsection 
deals with gene therapies by individual SOD isoforms (alone or combined with other genes) 
and about their influence on the mechanisms of the cardiovascular disease. 
4.2 Antioxidant gene therapy of the cardiovascular system with the SOD 1 gene  
The connection between the influence of angiotensin II (Ang II) and the increased 
superoxide production by activation of NAPDH oxidase has been observed in animal 
studies (Paravicini and Touyz, 2004; Zimmerman et al., 2004, Chan et al., 2005) and patients 
with cardiovascular complications (Yokoyama et al., 2000). Peripheral angiotensin II exerts 
potent effects on blood pressure and cardiovascular function through its actions on neurons 
located in specialized brain regions called the circumventricular organs, in particular the 
subfornical organ (SFO). Zimmerman et al., (2004) reported that following peripheral 
infusion of Ang II at initially subpressor doses, there was a gradually developing 
hypertension paralleled by an increase in superoxide production in the SFO. Using the 
adenoviral vectors for in vivo gene delivery, they found that both the superoxide production 
and the hypertension were prevented by an overexpression of CuZnSOD (also known as 
SOD1) in the SFO, whereas ECSOD (also known as SOD3) was ineffective. Ang II receptors 
are also highly expressed in brain stem cardiovascular centers, including the rostral 
ventrolateral medulla (RVLM) and nucleus tractus solitarii (NTS). Activation of Ang II 
receptors in the RVLM (Gao et al., 2004; Kishi et al., 2004; Chan et al., 2005) or NTS (Hirooka, 
2008) promotes neurogenic hypertension. This induced hypertension can also be prevented 
by protection against oxidative stress via treatment with in situ gene transduction of SOD1 
(Chan et al., 2006). Using a gene therapy based on SOD1 gene transduction by a bacterial 
gene delivery system it was found that such application decreases the blood pressure, 
regulates SOD and NOS activities, and decreases oxidative stress response (Dovinova et al., 
2008).  
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The overexpression of cytoplasm-targeted superoxide dismutase via an adenoviral vector 
(AdSOD1) efficiently scavenges angiotensin-II–induced increases in intracellular 
superoxide, markedly attenuates the increase in [Ca2+]i and suggests a potential intracellular 
signaling mechanism involved in Ang II–mediated oxidant regulation of central neural 
control of blood pressure (Zimmerman et al., 2005).Genetically-altered mice and rats have 
been generated which overexpress SOD1. Compared with nontransgenic controls, mRNA 
for CuZn-SOD1 and SOD activity are increased several-fold in the vascular and non-
vascular tissues, decreased vascular superoxide levels in atherosclerosis and diabetes to 
improve endothelial function and to protect in a model of fluid percussion injury that 
produces impairment of autoregulation (Faraci & Didion, 2004) 
Downregulation of antioxidant gene expression and enzyme activity may underlie the 
augmented levels of superoxide and hydrogen peroxide in the RVLM, leading to oxidative 
stress and hypertension in the spontaneously hypertensive rats (SHR). A causative 
relationship between biochemical correlates of oxidative stress and neurological 
hypertension was established after a gene transfer by microinjection of adenovirus encoding 
SOD1 and MnSOD (also known as SOD2) or catalase (CAT) into brain (RVLM), which 
promoted a long-term reduction of blood pressure in SHR (Chan et al., 2006).  
4.3 Antioxidant gene therapy of the mitochondrial dysfunction with the SOD 2 gene 
Mitochondrial dysfunction is a prominent feature of most cardiovascular diseases and 
hypertension and is associated with the deterioration of mitochondrial energy production in 
several organs such as the liver, the heart and the brain (Chan et al., 2009a, b). In the 
myocardium of the SHR, the evidence that points to the occurrence of mitochondrial 
dysfunction includes the decrease of cytochrome oxidase activity, ATP production, and 
inorganic phosphate translocator activity (de Cavanagh et al., 2006). Attenuated intracellular 
ATP content, results in a long-term maintenance of elevated blood pressure by increasing in 
sympathetic outflow, whereas augmented ROS production following mitochondrial 
dysfunction lowers the capacity of the NO-dependent vascular relaxation. The stationary 
elevated blood pressure in chronic arterial hypertension should be regarded as a 
compensatory response to decreased mitochondrial ATP synthesis (Postnov et al., 2007).  
Depletion of p22phox subunit of NADPH oxidase with small interfering RNA inhibited Ang 
II–mediated mitochondrial ROS production. Ang II depletes mitochondrial glutathione, 
increases state 4 and decreased state 3 respirations, and diminishes the mitochondrial 
respiratory control ratio. It also prevents the Ang II–induced decrease in endothelial NO and 
mitochondrial membrane potential. Therefore, Ang II induces mitochondrial dysfunction 
via a protein kinase C–dependent pathway by activating the endothelial cell NADPH 
oxidase and formation of peroxynitrite. Furthermore, mitochondrial dysfunction in response 
to Ang II modulates endothelial NO and superoxide generation, which in turn has 
ramifications for the development of an endothelial dysfunction (Doughan et al., 2008). In 
the brain stem cardiovascular neurons in the RVLM, mitochondrial superoxide mediates the 
rebound hypertension induced by the eNOS transgene in SHR (Kung et al., 2008). 
Mice lacking iNOS(-/-) exhibits extensive cytoplasmic swelling and degeneration of 
mitochondria, decrease in the resting indices of cardiac function as well as an impairment in 
the positive inotropic actions of isoproterenol following treatment with adriamycin 
compared to nTg mice. Cardiac troponin, creatine phosphokinase, and lactate 
dehydrogenase levels are significantly increased after adriamycin treatment in iNOS(-/-) 
mice However, when iNOS(-/-) mice are crossed with SOD2 overexpressing animals, 
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mitochondrial injury is ameliorated to the level of the wild type (Cole, 2006). Mice 
completely deficient in Mn-SOD die within a few weeks after birth and exhibit a variety of 
phenotypes (depending on the genetic background) including neurodegeneration, cardiac 
abnormalities, and extensive mitochondrial damage (Faraci & Didion, 2004) 
In Ang II-induced neurogenic hypertension or in SHR, mitochondrial electron transport 
capacity in the RVLM is reduced, accompanied by an increase in generation of 
mitochondrial superoxide and hydrogen peroxide (Chan et al., 2009a). Overexpression of 
SOD2 ameliorates mitochondrial oxidative stress and the induced antihypertension.  
4.4 Antioxidant gene therapy of the cardiovascular system with the SOD 3 gene and 
RNA silencing 
The degree of hypertrophy, ventricular dilatation, and myocardial fibrosis was markedly 
increased in mice lacking extracellular SOD (SOD3) and gene transfer of cDNA encoding 
membrane-bound SOD3 reduces vascular superoxide levels as well as arterial pressure in 
SHR (Chu et al., 2009). A deficiency in SOD3 does not alter the baseline blood pressure but 
increases the arterial pressure in models of hypertension that are greater in SOD3–deficient 
mice than in controls. Studies using overexpression strategies have revealed protective 
effects of SOD3 on blood vessels. Gene transfer of SOD3 reduced vascular superoxide levels 
during atherosclerosis in SHR. Effects of overexpression of SOD3 using this approach on 
endothelial function have varied (Faraci & Didion, 2004). 
Depletion of NADPH oxidase subunits with small interfering RNAs - another approach in 
gene therapy - inhibits ROS production and, thus, has the potential to reduce blood 
pressure. Silencing of p22phox component of NADPH oxidase in vivo by RNAi resulted in 
reduced ROS and mean atrial pressure in angiotensin II-induced hypertension in rats 
(Modlinger et al., 2006). Knock-down of several molecular targets by silencing of matrix 
metalloproteinase-7 (Wang et al., 2009), angiotensin-converting enzyme (He et al., 2009) or 
β1-adrenergic receptor (Arnold et al., 2007) using systemic RNAi results in attenuation of 
hypertension and stops the development of cardiac hypertrophy in SHR.  
5. Conclusion 
Modulation of angiogenesis is of great importance from experimental, pathophysiological 
and especially clinical point of view. However, further research is needed to fully delineate 
the most effective way to target angiogenesis for treatment of cancer and cardiovascular 
diseases. The application of new approaches using bacteria for the transfer of therapeutic 
genes or the production of therapeutic protein or small RNAs has the potential to 
significantly advance cancer gene therapy. Recent studies indicate that treatments targeting 
a single molecule/pathway, even if it has pleiotropic effects, are unlikely to be completely 
effective; however, if the natural anti-tumor activity inherent to some anaerobic bacteria 
strains can be successfully combined with their ability to deliver agents targeting tumor 
angiogenesis, apoptosis or the immune system, this will represent a significant step toward 
reaching this important goal.  
This chapter summarizes the preclinical and clinical studies and the use of animal models to 
provide evidence for potential benefit from angiogenic and antioxidant gene therapy. Gene 
therapy with the use of antioxidant genes may offer a promising approach for treatment of 
cancer and cardiovascular diseases in patients not suitable for conventional therapies. 
However, one must realize that in animal models before the experimental data can be 
translated to clinical trials, shortcomings of antioxidant gene therapy, for example the 
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limited duration of transgene expression, low efficacy of the transgene expression in the 
target organs or tissues, and potential immune responses to the transgenes, must be 
resolved. Specifically related to the use of antioxidant enzymes in gene therapy is the fact 
that reactive oxygen species not only mediate pathological events but are also required for 
normal cell signaling. This double-edged sword nature of the reactive oxygen species in 
regulation of cellular phenotypes under physiological and pathological conditions poses 
challenges to the application of gene therapy for early treatment of disease condition. 
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